Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,313.70INR
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
Rs2,313.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,030
52-wk High
Rs3,203.95
52-wk Low
Rs1,901.65

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.13
Market Cap(Mil.): Rs393,402.09
Shares Outstanding(Mil.): 165.89
Dividend: 20.00
Yield (%): 0.84

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA ‍​For Facility In Hyderabad

* SAYS GETS EIR FROM U.S. FDA ‍​FOR CUSTOM PHARMA SERVICES FACILITY IN HYDERABAD Source text - http://bit.ly/2ANfrXj Further company coverage:

Dec 01 2017

BRIEF-Dr.Reddy's Labs Gets U.S. FDA Nod For Psoriasis Treatment

* SAYS CO, THROUGH UNIT, GETS NDA NOD FOR PSORIASIS TREATMENT Source text: http://bit.ly/2kd95cA Further company coverage:

Nov 30 2017

BRIEF-Dr.Reddy's Laboratories gets German Regulator's Nod For CAPA Plan

* SAYS GERMAN REGULATOR PERMITTED PRODUCTION TO START AGAIN FROM FACILITY FOR EU MARKET‍​

Nov 30 2017

BRIEF-Dr.Reddy's Labs Says U.S. Securities Classs Action Lawsuit Been Served On Co

* SAYS U.S. SECURITIES CLASSS ACTION LAWSUIT BEEN SERVED ON CO BY LAWFIRM REPRESENTING INVESTORS IN CO Source text - http://bit.ly/2zOAdWp Further company coverage:

Nov 29 2017

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Duvvada facility

* Says got EIR from US FDA for formulations manufacturing facility at Duvvada, Vishakhapatnam‍​

Nov 20 2017

BRIEF-Dr.Reddy's Labs ‍launches clofarabine injection in U.S.

* Says ‍launch of clofarabine injection in U.S. market​ Source text: http://bit.ly/2zBoR7i Further company coverage:

Nov 14 2017

BRIEF-DR. REDDY'S LABORATORIES LAUNCHES GENERIC AZACITIDINE FOR INJECTION IN CANADIAN MARKET

* DR REDDY'S LABORATORIES ANNOUNCES THE LAUNCH OF GENERIC AZACITIDINE FOR INJECTION IN THE CANADIAN MARKET

Nov 02 2017

BRIEF-India's Dr.Reddy's Laboratories Sept-qtr consol PAT down about 1 pct

* Sept quarter consol net profit after tax 3.05 billion rupees versus 3.09 billion rupees last year

Oct 31 2017

BRIEF-Enorama Pharma ‍starts cooperation with Dr. Reddy's Laboratories

* ‍STARTS COOPERATION WITH DR. REDDY'S LABORATORIES ON SALES IN NORTH AMERICA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 12 2017

Indian shares head for 3rd session of gains; automakers jump on Sept sales

Oct 3 Indian shares rose over 1 percent on Tuesday and were headed for a third consecutive session of gains, as automakers such as Tata Motors Ltd surged after posting strong monthly sales, while Dr. Reddy's Laboratories jumped on the launch of a drug in its key U.S. market.

Oct 03 2017

Earnings vs. Estimates